Mortality and progression to AIDS after starting highly active antiretroviral therapy
暂无分享,去创建一个
Mark A van de Wiel | Peter Reiss | Azra C Ghani | Frank de Wolf | Ard I van Sighem | Inge C Gyssens | A. Ghani | M. A. van de Wiel | P. Reiss | I. Gyssens | F. de Wolf | A. van Sighem | J. Lange | Mariëlle Jambroes | Kees Brinkman | Joep M A Lange | K. Brinkman | M. Jambroes
[1] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[2] P. Eilers,et al. Non-proportional hazards models in survival analysis , 2000 .
[3] Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population. , 2001, Journal of acquired immune deficiency syndromes.
[4] D. Revicki,et al. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease , 1998, AIDS.
[5] M Egger,et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. , 1999, JAMA.
[6] Richard D Moore,et al. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy , 2001, AIDS.
[7] P. Couzigou,et al. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? , 2002, AIDS.
[8] M. Lederman,et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995--1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] C. Sabin,et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre , 2001, AIDS.
[10] K. Hertogs,et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[11] D. Cooper,et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.
[12] M. Moroni,et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.
[13] D. Cooper,et al. Adverse effects of antiretroviral therapy , 2000, The Lancet.
[14] D. Richman,et al. Predictors of Self‐Reported Adherence and Plasma HIV Concentrations in Patients on Multidrug Antiretroviral Regimens , 2000, Journal of acquired immune deficiency syndromes.
[15] G. M. Ortiz,et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection , 2001, AIDS.
[16] T F Blaschke,et al. Patient compliance and drug failure in protease inhibitor monotherapy. , 1996, JAMA.
[17] A. Mocroft,et al. Relations among CD4 Lymphocyte Count Nadir, Antiretroviral Therapy, and HIV-1 Disease Progression: Results from the EuroSIDA Study , 1999, Annals of Internal Medicine.
[18] Manuel Battegay,et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study , 1997, BMJ.
[19] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[20] D Johnson,et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. , 1999, AIDS.
[21] JD Lundgren,et al. Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.
[22] D. Revicki,et al. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter , 1999 .
[23] R. Paredes,et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection , 2001, AIDS.
[24] Roger Detels,et al. Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.
[25] R. Weber,et al. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l , 2002, AIDS.
[26] Michael S Saag,et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. , 2002, JAMA.
[27] Jonathan AC Sterne,et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.
[28] S. Paulous,et al. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. , 1999, AIDS.
[29] H. Furrer,et al. Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study , 2002, AIDS.
[30] John W. Ward,et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[31] A. Telenti,et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.
[32] I Spijkerman,et al. AIDS prognosis based on HIV‐1 RNA, CD4+ T‐cell count and function: markers with reciprocal predictive value over time after seroconversion , 1997, AIDS.
[33] M. Sprangers,et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. , 2001, Archives of internal medicine.